Craig Venter says that he has been "successful in is finding alternate ways to fund research," in the New York Times. A venture capitalist friend, Alan Walton, adds that "Craig is just a hopeless businessman." Venter began Synthetic Genomics as a way to fund his research in synthetic biology, and his work there has garnered attention — Venter notes he heard from the president and the pope on the same day after announcing the activation of a synthetic genome. However, Synthetic Genomics has attracted a lot of funding, too, notes the Times, with investments from various venture capital firms, ExxonMobil, BP, a Malaysian conglomerate, a Mexican industrialist, among others. Venter is driven, the Times adds, by "the desire for scientific accomplishments, publications and recognition, and for the Nobel Prize that still eludes him. Business is just a means to a scientific end."
Craig Venter, "Hopeless Businessman"
Sep 06, 2010